Cytosorbents (CTSO) Registration Filing summary

Company overview and business model

• Specializes in blood purification technologies for critical care and cardiac surgery, leveraging proprietary polymer adsorption technology with a broad product portfolio and global reach.

• Flagship product is commercialized in the EU and other markets, targeting life-threatening inflammation and organ failure; additional products are in development for various medical and veterinary applications.

• Holds 22 issued U.S. patents and multiple international patents, with a focus on expanding regulatory approvals and clinical indications.

• Pursuing U.S. and Canadian market entry for its antithrombotic removal system, with regulatory submissions expected in Q3 2024.

• Emphasizes growth through regulatory expansion, sales initiatives, and cost control.

Financial performance and metrics

• Identified as a smaller reporting company, with less than $250 million in public float or less than $100 million in annual revenues and less than $700 million in public float.

• Most recent audited financial statements include a going concern explanatory paragraph from the independent auditor.

Use of proceeds and capital allocation

• Net proceeds are expected to be used for general corporate purposes, including funding clinical studies, manufacturing, sales and marketing, debt repayment, and product development.

• Management retains broad discretion over allocation of proceeds.